{"title":"Psoriasis and Atopic Dermatitis Overlap: Pathogenesis and Therapeutic Considerations for the Clinician.","authors":"Sammer Marzouk, Peter Lio","doi":"10.1177/17103568251378145","DOIUrl":null,"url":null,"abstract":"<p><p><u><b><i></i></b></u> Psoriasis (PsO) and atopic dermatitis (AD) are chronic, inflammatory skin diseases with distinct, yet occasionally overlapping, immunological profiles. PsO is characterized by T helper (Th) 1/Th17 immune pathways, while AD predominantly involves Th2 responses. However, a subset of patients exhibit features of both conditions, presenting a diagnostic and therapeutic challenge. This review aims to comprehensively assess the pathogenesis, clinical presentation, and therapeutic considerations of the PsO-AD overlap phenotype. This unique clinical entity is characterized by mixed Th17/Th2 immune responses, including elevated levels of interleukin (IL)-17A, IL-23, IL-4, and IL-13, complicating diagnosis and treatment strategies. Recent insights into the genetic, immunological, and environmental contributors to this phenotype, alongside emerging biomarker-guided therapies, offer potential for more precise management.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatitis : contact, atopic, occupational, drug","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17103568251378145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Psoriasis (PsO) and atopic dermatitis (AD) are chronic, inflammatory skin diseases with distinct, yet occasionally overlapping, immunological profiles. PsO is characterized by T helper (Th) 1/Th17 immune pathways, while AD predominantly involves Th2 responses. However, a subset of patients exhibit features of both conditions, presenting a diagnostic and therapeutic challenge. This review aims to comprehensively assess the pathogenesis, clinical presentation, and therapeutic considerations of the PsO-AD overlap phenotype. This unique clinical entity is characterized by mixed Th17/Th2 immune responses, including elevated levels of interleukin (IL)-17A, IL-23, IL-4, and IL-13, complicating diagnosis and treatment strategies. Recent insights into the genetic, immunological, and environmental contributors to this phenotype, alongside emerging biomarker-guided therapies, offer potential for more precise management.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
